Exenatide
GLP-1 receptor agonist · Antidiabetic · First-in-class incretin mimetic
Exenatide
Byetta (twice-daily), Bydureon BCise (weekly)
Exenatide is the first-in-class GLP-1 receptor agonist, approved by the FDA in April 2005 (Byetta, twice-daily subcutaneous)[3] and later as an extended-release weekly formulation (Bydureon, January 2012; reformulated as Bydureon BCise in 2017).[4]
Avoid. Animal embryofetal toxicity is documented.[3] Byetta's short half-life means rapid washout (days); Bydureon's slow microsphere release means a much longer effective washout (weeks to months).[4]
GLP-1 receptor agonist · Semaglutide · Liraglutide · Dulaglutide · Tirzepatide · Gila monster · Type 2 diabetes mellitus
Exenatide is a synthetic version of exendin-4, originally isolated by John Eng at the Bronx VA Medical Center in 1992 from the saliva of the Gila monster (Heloderma suspectum).[1] The peptide is only 53% homologous to native human GLP-1 but is naturally resistant to DPP-4 — that natural resistance is what made it the first clinically usable incretin mimetic, validating the GLP-1 receptor as a therapeutic target and opening the path to all subsequent agents in the class.
In contrast to the long-acting weekly agents that followed, exenatide carries a heavier GI side-effect burden (especially Byetta BID) and is associated with anti-exenatide antibody formation in a substantial minority of users — antibodies that can reduce efficacy.[3] Twice-daily Byetta was discontinued in the United States in 2024.[citation needed] Bydureon BCise remains available but is no longer commonly prescribed first-line.Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
<indication ref="diabetes-type-2" author="MDElliottMD"/>
+ Add a problemTitration strategies
Byetta — standard T2DM titration0
Bydureon BCise — standard T2DM dosing0
2 mg SC once weekly, same day each week, no titration required.[4]
Steady-state plasma exenatide is reached only after 6–7 weeks of dosing — counsel patients that the medicine will keep ramping up well after the first injection. HbA1c response should be assessed at 12+ weeks, not earlier.[4]
Renal dosing: avoid if CrCl <45 mL/min.[4]Effects
- Nausea — historically the highest of any GLP-1 RA. ~40–50% of Byetta BID users report nausea; ~20% with Bydureon weekly.[3][4]
- Vomiting, diarrhea, constipation, dyspepsia[3]
- Injection-site reactions — notably higher with Bydureon (small nodules at injection sites are common, often visible/palpable for weeks)[4]
- Anti-exenatide antibodies — form in ~40% of users; high titers correlate with reduced glycemic efficacy[3]
- Headache, jitteriness (less common)[citation needed]
Pharmacokinetics
Byetta (BID): rapid absorption, peak ~2.1 h, half-life ~2.4 h. Renal elimination predominates (unlike most other GLP-1 RAs); dose adjustment required for CrCl 30–50, contraindicated <30.[3]
Bydureon BCise (weekly): exenatide is encapsulated in slow-release biodegradable polymer microspheres; multiple peaks occur as successive microsphere cohorts release the peptide. Steady-state plasma levels are reached only after 6–7 weeks of weekly dosing — meaning early efficacy looks weaker than other weekly GLP-1 RAs.[4]Pharmacodynamics
At maintenance doses:
- HbA1c reduction of ~0.8–1.0 percentage points (Byetta 10 µg BID or Bydureon 2 mg/wk)[3][4]
- Weight loss of ~2–3 kg[3]
- Cardiovascular outcomes: non-inferior but not superior to placebo in T2DM (EXSCEL) — the only major GLP-1 RA CVOT not to demonstrate superiority[5]
Interactions
No interactions reported yet.
Pregnancy and lactation
Monitoring
- Baseline: HbA1c, weight, BP, renal function (especially important for exenatide — renally cleared)[3]
- Personal or family history of MTC or MEN2 — contraindicated, do not start (Bydureon only — Byetta's label predates the class boxed warning conversion)[4]
- Every 3 months for first year: HbA1c, weight, GI tolerability, renal function, signs of pancreatitis or gallbladder disease
- Pre-procedure: Byetta — skip the dose before the procedure; Bydureon — hold weekly dose ≥7 days pre-op[6]
Patient counseling
- Byetta: inject within 60 min before a meal (not after). Skip the dose if you skip the meal.[3]
- Bydureon: same day each week. Suspension must be activated by vigorous shaking until uniformly cloudy — administration immediately after mixing is required.[4]
- Expect small injection-site nodules with Bydureon — these are the polymer microspheres and usually resolve over weeks to months.[4]
- GI side effects with Byetta BID peak in the first 8 weeks and often improve.[3]
- Surgery: hold Bydureon ≥7 days pre-op; for Byetta, skip the pre-procedure dose.[6]
Relevant anecdote
0
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
See also
References
- ↑ 1.0 1.1 Eng J, Kleinman WA, Singh L et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 267(11):7402–5.
- ↑ Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 US FDA. Byetta (exenatide) prescribing information. AstraZeneca. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 US FDA. Bydureon BCise (exenatide extended-release) prescribing information. AstraZeneca. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209210s000lbl.pdf
- ↑ Holman RR, Bethel MA, Mentz RJ et al. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). NEJM 377(13):1228–39. doi:10.1056/NEJMoa1612917
- ↑ 6.0 6.1 Kindel TL et al. (2024). Perioperative GLP-1 receptor agonist safety guidance. Surg Obes Relat Dis 20(12):1183–8.
[[File:Exendin-4 — a 39-amino-acid peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum). Only 53% homologous with human GLP-1 but naturally resistant to DPP-4 cleavage because of a glycine at position 2.[1]|frameless|240px|alt=Structure of Exenatide]]
Pharmacy
Starting dose
Preparations
Pharmacology
Routes
Subcutaneous (abdomen, thigh, upper arm)[3]
Onset
Glycemic effect within hours (Byetta); weeks (Bydureon — extended-release microsphere)[4]
Duration
Half-life
Bioavailability
SC ~65%–75%[citation needed]
Pregnancy
Avoid. Discontinue before planned pregnancy.[3]
Legal status
Rx-only;[3] not a controlled substance
Purported mechanism
Selective agonist of the GLP-1 receptor. Mechanism identical to other GLP-1 RAs (glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression).[2]